LRI Investments LLC Has $1.12 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

LRI Investments LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 1.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,060 shares of the company’s stock after purchasing an additional 176 shares during the quarter. LRI Investments LLC’s holdings in Novo Nordisk A/S were worth $1,123,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Center for Financial Planning Inc. raised its position in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after buying an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL boosted its position in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares in the last quarter. Transce3nd LLC bought a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $39,000. Finally, Albion Financial Group UT raised its position in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.4%

Shares of NVO stock opened at $65.75 on Monday. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The stock’s fifty day simple moving average is $69.21 and its 200 day simple moving average is $85.83. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $295.06 billion, a P/E ratio of 19.98, a P/E/G ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The company had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $79.17 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Ratings Changes

NVO has been the topic of a number of research analyst reports. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an “underperform” rating on the stock. Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Finally, Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.